Title:
A Phase III, Randomized, Open-Label, Multicenter, Global Study of Volrustomig (MEDI5752) in Combination With Carboplatin Plus Pemetrexed Versus Platinum Plus Pemetrexed or Nivolumab Plus Ipilimumab in Participants With Unresectable Pleural Mesothelioma (eVOLVE-Meso)
Phase:
III
Contact:
Petra Kettenring / Kontaktperson
Clinical Investigator:
Dr. med. Rajiv Shah
Registration:
Die Studie ist bei den U.S. National Institutes of Health(ClinicalTrials.gov) registriert. Siehe
NCT06097728
